Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142337 | 1.00 | F10 (0.67) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL3142323 | 0.91 | F10 (0.59) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL3150504 | 0.91 | F10 (0.62) | F10ABCB11F2ST14 | |
| SCHEMBL3151258 | 0.91 | F10 (0.55) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL3151478 | 0.91 | F10 (0.58) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL3150382 | 0.91 | F10 (0.68) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL3151508 | 0.90 | F10 (0.69) | F10ABCB11F2ST14 | |
| SCHEMBL3155737 | 0.90 | F10 (0.65) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL3142255 | 0.90 | F10 (0.67) | F10ABCB11F2ST14CYP1A2 | |
| SCHEMBL3155698 | 0.90 | F10 (0.56) | F10ABCB11F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099453-B1 | Combination therapy of substituted oxazolidinones | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | claimed |
| EP-2560964-A1 | PROCESS FOR PREPARING 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | Euticals GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| WO-2011131316-A1 | PROCESS FOR PREPARING 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | ARCHIMICA GMBH (DE) | 2011-10-27 | — | — | WO | claimed |
| EP-1720866-B1 | PRODUCTION METHOD | BAYER SCHERING PHARMA AG (DE) | 2011-08-03 | — | — | EP | claimed |
| JP-4667044-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1583761-B1 | METHOD FOR PRODUCING 5-CHLORO- i N /i -({5 i S /i )-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&rc ub;-METHYL)-2-THIOPHENE CARBOXAMIDE | BAYER SCHERING PHARMA AG (DE) | 2011-02-23 | — | — | EP | claimed |
| EP-1411932-B1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER SCHERING PHARMA AG (DE) | 2010-02-10 | — | — | EP | claimed |
| US-20100003542-A1 | Coating of artificial surfaces of medical aids and instruments, and cleaning and/or pretreatment of catheters and other medical aids and instruments | BAYER SCHERING PHARMA AKTIENGESSELSCHAFT (DE) | 2010-01-07 | — | — | US | claimed |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | claimed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| JP-2007517816-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1720866-A1 | PRODUCTION METHOD | Bayer HealthCare AG (DE) | 2006-11-15 | — | — | EP | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| JP-2006513227-A | — | — | 2006-04-20 | — | — | JP | claimed |
| EP-1583761-A1 | METHOD FOR PRODUCING 5-CHLORO- i N /i -({5 i S /i )-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&rc ub;-METHYL)-2-THIOPHENE CARBOXAMIDE | Bayer HealthCare AG (DE) | 2005-10-12 | — | — | EP | claimed |
| WO-2005068456-A1 | PRODUCTION METHOD | BAYER HEALTHCARE AG (DE) | 2005-07-28 | — | — | WO | claimed |
| WO-2004060887-A1 | METHOD FOR PRODUCING 5-CHLORO-N-({5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDIN-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2004-07-22 | — | — | WO | claimed |
| EP-2099453-B1 | Combination therapy of substituted oxazolidinones | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-1261606-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | Bayer Aktiengesellschaft (DE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001047919-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | PEPD, PLAT, TFPI | F10 51/4885ABCB11 1508/4885F2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.